| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CONCISE REVIEW |
Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Key Words. Leukemia inhibitory factor • Embryonic stem cells • Polyfunctionality
Donald Metcalf, A.C., M.D., Professor Emeritus, Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville Victoria 3050, Australia. Telephone: 61-3-9345-2555; Fax: 61-3-9347-0852; e-mail: metcalf{at}wehi.edu.au
Leukemia inhibitory factor (LIF) is a polyfunctional glycoprotein cytokine whose inducible production can occur in many, perhaps all, tissues. LIF acts on responding cells by binding to a heterodimeric membrane receptor composed of a low-affinity LIF-specific receptor and the gp130 receptor chain also used as the receptor for interleukin-6, oncostatin M, cardiotrophin-1, and ciliary neurotrophic factor. LIF is essential for blastocyst implantation and the normal development of hippocampal and olfactory receptor neurons. LIF is used extensively in experimental biology because of its key ability to induce embryonic stem cells to retain their totipotentiality. LIF has a wide array of actions, including acting as a stimulus for platelet formation, proliferation of some hematopoietic cells, bone formation, adipocyte lipid transport, adrenocorticotropic hormone production, neuronal survival and formation, muscle satellite cell proliferation, and acute phase production by hepatocytes. Unwanted actions of LIF can be minimized by circulating soluble LIF receptors and by intracellular suppression by suppressors of cytokine-signaling family members. However, the outstanding problems remain of how the induction of LIF is mediated in response to demands from such a heterogeneity of target tissues and why it makes design sense to use LIF in the regulation of such a diverse and unrelated series of biological processes.
This article has been cited by other articles:
|
|
 |
|
  R. A. Linker, N. Kruse, S. Israel, T. Wei, S. Seubert, A. Hombach, B. Holtmann, F. Luhder, R. M. Ransohoff, M. Sendtner, et al. Leukemia Inhibitory Factor Deficiency Modulates the Immune Response and Limits Autoimmune Demyelination: A New Role for Neurotrophic Cytokines in Neuroinflammation J. Immunol., February 15, 2008; 180(4): 2204 - 2213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Metcalf Hematopoietic cytokines Blood, January 15, 2008; 111(2): 485 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Duluc, Y. Delneste, F. Tan, M.-P. Moles, L. Grimaud, J. Lenoir, L. Preisser, I. Anegon, L. Catala, N. Ifrah, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells Blood, December 15, 2007; 110(13): 4319 - 4330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. White, J.-G. Zhang, L. A. Salamonsen, M. Baca, W. D. Fairlie, D. Metcalf, N. A. Nicola, L. Robb, and E. Dimitriadis From the Cover: Blocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: A nonhormonal contraceptive strategy PNAS, December 4, 2007; 104(49): 19357 - 19362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sun, K. Ma, H. Wang, F. Xiao, Y. Gao, W. Zhang, K. Wang, X. Gao, N. Ip, and Z. Wu JAK1 STAT1 STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts J. Cell Biol., October 8, 2007; 179(1): 129 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Huyton, J.-G. Zhang, C. S. Luo, M.-Z. Lou, D. J. Hilton, N. A. Nicola, and T. P. J. Garrett An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor PNAS, July 31, 2007; 104(31): 12737 - 12742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Magni, E. Dozio, M. Ruscica, H. Watanobe, A. Cariboni, R. Zaninetti, M. Motta, and R. Maggi Leukemia Inhibitory Factor Induces the Chemomigration of Immortalized Gonadotropin-Releasing Hormone Neurons through the Independent Activation of the Janus Kinase/Signal Transducer and Activator of Transcription 3, Mitogen-Activated Protein Kinase/Extracellularly Regulated Kinase 1/2, and Phosphatidylinositol 3-Kinase/Akt Signaling Pathways Mol. Endocrinol., May 1, 2007; 21(5): 1163 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wysoczynski, K. Miekus, K. Jankowski, J. Wanzeck, S. Bertolone, A. Janowska-Wieczorek, J. Ratajczak, and M. Z. Ratajczak Leukemia Inhibitory Factor: A Newly Identified Metastatic Factor in Rhabdomyosarcomas Cancer Res., March 1, 2007; 67(5): 2131 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Price, D. A. Long, N. Jina, H. Liapis, M. Hubank, A. S. Woolf, and P. J. D. Winyard Microarray interrogation of human metanephric mesenchymal cells highlights potentially important molecules in vivo Physiol Genomics, January 17, 2007; 28(2): 193 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O Huising, C. P Kruiswijk, and G. Flik Phylogeny and evolution of class-I helical cytokines. J. Endocrinol., April 1, 2006; 189(1): 1 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Takaki, M. Fujimoto, K. Sugahara, T. Nakahari, S. Yonemura, Y. Tanaka, N. Hayashida, S. Inouye, T. Takemoto, H. Yamashita, et al. Maintenance of Olfactory Neurogenesis Requires HSF1, a Major Heat Shock Transcription Factor in Mice J. Biol. Chem., February 24, 2006; 281(8): 4931 - 4937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Song and H. Lim Evidence for heterodimeric association of leukemia inhibitory factor (LIF) receptor and gp130 in the mouse uterus for LIF signaling during blastocyst implantation Reproduction, February 1, 2006; 131(2): 341 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zvonic, J. E. Baugh Jr., P. Arbour-Reily, R. L. Mynatt, and J. M. Stephens Cross-talk among gp130 Cytokines in Adipocytes J. Biol. Chem., October 7, 2005; 280(40): 33856 - 33863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Spangenburg SOCS-3 Induces Myoblast Differentiation J. Biol. Chem., March 18, 2005; 280(11): 10749 - 10758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hoek, D. L. Rimm, K. R. Williams, H. Zhao, S. Ariyan, A. Lin, H. M. Kluger, A. J. Berger, E. Cheng, E. S. Trombetta, et al. Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas Cancer Res., August 1, 2004; 64(15): 5270 - 5282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Gonzalez, B. R. Rueda, M. P. Ramos, R. D. Littell, S. Glasser, and P. C. Leavis Leptin-Induced Increase in Leukemia Inhibitory Factor and Its Receptor by Human Endometrium Is Partially Mediated by Interleukin 1 Receptor Signaling Endocrinology, August 1, 2004; 145(8): 3850 - 3857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Classen-Linke, G. Muller-Newen, P.C. Heinrich, H.M. Beier, and U. von Rango The cytokine receptor gp130 and its soluble form are under hormonal control in human endometrium and decidua Mol. Hum. Reprod., July 1, 2004; 10(7): 495 - 504. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
